Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35078 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Sebastian A Wohlfeil und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Neoplasm Recurrence, Local, Pyrimidinones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Stiftung Dermatologie e.V. (Deutsche Dermatologische Gesellschaft e.V. (DDG)/Arbeitsgemeinschaft Dermatologische Forschung e.V. (ADF)).
Abstract (Originalsprache)
This study investigated whether adjuvant treatments in stage III cutaneous melanoma (CM) influenced patterns of recurrence. Patients with primary ( n = 1033) or relapsed CM ( n = 350) who received adjuvant therapies with Nivolumab (N), Pembrolizumab (P), or Dabrafenib and Trametinib (D + T) were extracted from the prospective multicenter real‐world skin cancer registry ADOReg. Endpoints were progression‐free survival (PFS), distant metastasis‐free survival (DMFS), organ‐specific DMFS, and overall survival (OS). For primary cases, D + T indicated an improved PFS (1‐ and 2‐year PFS: 90.9%; 82.7%) as compared to P (81.0%, 73.9%; p = .0208), or N (83.8%, 75.2%; p = .0539). BRAF ‐mutated(mut) CM demonstrated significantly lower PFS ( p = .0022) and decreased DMFS ( p = .0580) when treated with immune checkpoint inhibitor (ICI) instead of D + T. Besides, NRAS ‐mut CM tended to perform worse than wt CM upon ICI (PFS: p = .1349; DMFS: p = .0540 ) . OS was similar between the groups. Relapsed cases showed decreased PFS, DMFS, and OS in comparison to primary (all: p < .001), without significant differences between the subgroups. Organ‐specific DMFS was significantly altered for primary cases with bone ( p = .0367) or brain metastases ( p = .0202). In relapsed CM, the frequency of liver (D + T: 1.5%; P: 12%; N: 9%) and LN metastases (D + T: 1.5%; P: 12%; N: 10.2%) was significantly lower with adjuvant D + T than ICI. NRAS ‐mut CM showed increased recurrence in primary and relapsed cases. These data show that adjuvant D + T is superior to ICI in primary BRAF ‐mut CM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, Mannheim, Germany.
- Section of Clinical and Molecular Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
- Department for Statistical Analysis, University Medical Center Mannheim, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Heidelberg, Germany.
- Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
ORCID-Profile: Sebastian A Wohlfeil
Förderung
- Deutsche Forschungsgemeinschaft
- Deutsche Stiftung Dermatologie e.V. (Deutsche Dermatologische Gesellschaft e.V. (DDG)/Arbeitsgemeinschaft Dermatologische Forschung e.V. (ADF))
Zitieren
APA
Wohlfeil, S. A., Kranzmann, L., Weiß, C., von Wasielewski, I., Klespe, K. C., Kähler, K. C., Weichenthal, M., Schadendorf, D., Zimmer, L., Mohr, P., Meier, F., Pfoehler, C., Berking, C., Heppt, M. V., Herbst, R., Kreuter, A., Gutzmer, R., Ulrich, J., Meiss, F., …, & Utikal, J. (2024). Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg. International Journal of Cancer. https://doi.org/10.1002/ijc.35078
Vancouver
Wohlfeil SA, Kranzmann L, Weiß C, von Wasielewski I, Klespe KC, Kähler KC, et al. Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg. International Journal of Cancer. 2024. doi:10.1002/ijc.35078
BibTeX
@article{Wohlfeil2024,
author = {Wohlfeil, Sebastian A and Kranzmann, Leonie and Weiß, Christel and von Wasielewski, Imke and Klespe, Kai C and Kähler, Katharina C and Weichenthal, Michael and Schadendorf, Dirk and Zimmer, Lisa and Mohr, Peter and Meier, Friedegund and Pfoehler, Claudia and Berking, Carola and Heppt, Markus V and Herbst, Rudolf and Kreuter, Alexander and Gutzmer, Ralf and Ulrich, Jens and Meiss, Frank and Gebhardt, Christoffer and Dippel, Edgar and Leiter, Ulrike and Schilling, Bastian and Ugurel, Selma and Utikal, Jochen},
title = {Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35078}
}
EUVIMED